Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BCG solution |
| Synonyms | |
| Therapy Description |
TICE BCG solution (BCG solution) is an attenuated live culture of Bacillus Calmette Guerin that induces anti-tumor immunity in bladder cancer (PMID: 26000263). TICE BCG solution (BCG solution) is FDA approved for carcinoma in situ of the bladder (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BCG solution | TICE BCG solution | Bacillus Calmette-Guerin solution | TICE BCG solution (BCG solution) is an attenuated live culture of Bacillus Calmette Guerin that induces anti-tumor immunity in bladder cancer (PMID: 26000263). TICE BCG solution (BCG solution) is FDA approved for carcinoma in situ of the bladder (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03528694 | Phase III | BCG solution + Durvalumab BCG solution | Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer | Active, not recruiting | POL | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 2 |
| NCT03091660 | Phase III | BCG Tokyo-172 Strain Solution BCG solution | Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
| NCT05714202 | Phase III | BCG solution Cetrelimab + TAR-200 TAR-200 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (SunRISe-3) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 7 |
| NCT03799835 | Phase III | Atezolizumab + BCG solution BCG solution | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN) | Active, not recruiting | FRA | ESP | BEL | 0 |
| NCT03711032 | Phase III | BCG solution + Pembrolizumab BCG solution | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | Active, not recruiting | USA | TUR | POL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | 10 |
| NCT04165317 | Phase III | BCG solution + PF-06801591 BCG solution | Study of PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer. (B8011006) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
| NCT04149574 | Phase III | BCG solution + Nivolumab BCG solution | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) | Terminated | USA | SWE | NLD | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 3 |
| NCT04630730 | Phase II | BCG solution Atezolizumab + Cisplatin + Gemcitabine | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | Recruiting | CHE | 0 |
CKB BOOST